AUR-112 / Dr. Reddy’s - LARVOL DELTA

Aurigene Oncology Limited Announces Encouraging Initial Data From 1^st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies (Businesswire) - "Pharmacodynamic data demonstrated rapid and sustained IL-2 inhibition, with all evaluated patients showing IL-2 levels below the limit of quantification by Cycle 1 Day 15. Efficacy: Among 11 efficacy-evaluable patients (all in 1st two cohorts), the overall response rate was 63.6%, including six partial responses and one complete response. Responses were observed in MCL, MZL, Hodgkin Lymphoma (HL), and Diffuse Large B-Cell Lymphoma (DLBCL)....Based on these encouraging results, the initiation of dose-expansion cohorts in select lymphoid malignancies, including Chronic Lymphocytic Leukemia (CLL), Waldenström’s Macroglobulinemia, MCL, and MZL are being planned."

P1 data • PK/PD data • Trial status • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Hodgkin Lymphoma • Mantle Cell Lymphoma • Marginal Zone Lymphoma • Waldenstrom Macroglobulinemia

ADITI-1: Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Lymphoma • Oncology

ADITI-1: Study Evaluating Safety Pharmacokinetics and Pharmacodynamics of AUR112 in Patients With Relapsed Advanced Lymphoma (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited

New P1 trial • Hematological Malignancies • Lymphoma • Oncology